CN111249396A - Traditional Chinese medicine for treating chronic gastritis and preparation method of micronized particles thereof - Google Patents
Traditional Chinese medicine for treating chronic gastritis and preparation method of micronized particles thereof Download PDFInfo
- Publication number
- CN111249396A CN111249396A CN202010179885.1A CN202010179885A CN111249396A CN 111249396 A CN111249396 A CN 111249396A CN 202010179885 A CN202010179885 A CN 202010179885A CN 111249396 A CN111249396 A CN 111249396A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- chinese medicinal
- medicinal materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 239000002245 particle Substances 0.000 title claims abstract description 35
- 208000007882 Gastritis Diseases 0.000 title claims abstract description 32
- 208000023652 chronic gastritis Diseases 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000000463 material Substances 0.000 claims abstract description 52
- 238000010298 pulverizing process Methods 0.000 claims abstract description 42
- 239000008187 granular material Substances 0.000 claims abstract description 37
- 239000000843 powder Substances 0.000 claims abstract description 27
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 24
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 24
- 241000270322 Lepidosauria Species 0.000 claims abstract description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 14
- 241000218176 Corydalis Species 0.000 claims abstract description 13
- 241000237502 Ostreidae Species 0.000 claims abstract description 13
- 235000020636 oyster Nutrition 0.000 claims abstract description 13
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 12
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 12
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 12
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 12
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 12
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 12
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 12
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 12
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 12
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 12
- 241000132446 Inula Species 0.000 claims abstract description 12
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 12
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 12
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 10
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000004806 packaging method and process Methods 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 238000005469 granulation Methods 0.000 claims description 16
- 230000003179 granulation Effects 0.000 claims description 16
- 238000004140 cleaning Methods 0.000 claims description 8
- 238000001125 extrusion Methods 0.000 claims description 7
- 238000007908 dry granulation Methods 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 5
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 3
- 239000002985 plastic film Substances 0.000 claims description 3
- 229920006255 plastic film Polymers 0.000 claims description 3
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims 2
- 241001313857 Bletilla striata Species 0.000 claims 1
- 235000008671 Calycanthus floridus Nutrition 0.000 claims 1
- 235000008670 Calycanthus occidentalis Nutrition 0.000 claims 1
- 244000148992 Lindera benzoin Species 0.000 claims 1
- 235000004520 Lindera benzoin Nutrition 0.000 claims 1
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 claims 1
- 240000000233 Melia azedarach Species 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims 1
- 241000915604 Scutellaria barbata Species 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 235000011477 liquorice Nutrition 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 22
- 241000249820 Lipotes vexillifer Species 0.000 abstract description 14
- 238000005516 engineering process Methods 0.000 abstract description 14
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 13
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 13
- 229940010454 licorice Drugs 0.000 abstract description 13
- 240000005717 Dioscorea alata Species 0.000 abstract description 12
- 244000237986 Melia azadirachta Species 0.000 abstract description 12
- 235000013500 Melia azadirachta Nutrition 0.000 abstract description 12
- 235000003143 Panax notoginseng Nutrition 0.000 abstract description 12
- 241000180649 Panax notoginseng Species 0.000 abstract description 12
- 235000004879 dioscorea Nutrition 0.000 abstract description 12
- 230000008569 process Effects 0.000 abstract description 6
- 235000003385 Diospyros ebenum Nutrition 0.000 abstract description 3
- 241000792913 Ebenaceae Species 0.000 abstract description 3
- 230000000975 bioactive effect Effects 0.000 abstract description 3
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 14
- 235000002723 Dioscorea alata Nutrition 0.000 description 11
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 11
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 11
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 11
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 11
- 241000202807 Glycyrrhiza Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 241001092040 Crataegus Species 0.000 description 10
- 241000207929 Scutellaria Species 0.000 description 10
- 210000001156 gastric mucosa Anatomy 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 235000007877 Diospyros australis Nutrition 0.000 description 8
- 240000002577 Prunus nigra Species 0.000 description 8
- 235000010875 Prunus nigra Nutrition 0.000 description 8
- 235000018288 Vitex doniana Nutrition 0.000 description 8
- 238000005485 electric heating Methods 0.000 description 7
- 241000411851 herbal medicine Species 0.000 description 7
- 235000007056 Dioscorea composita Nutrition 0.000 description 6
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 6
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000010072 ban-zhi-lian Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000253127 Inula conyza Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010067994 Mucosal atrophy Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 241001653634 Russula vesca Species 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/13—Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗慢性胃炎的中药及其微粉化颗粒的制备方法。其特点是,按照重量份计组成为:蜥蜴20~30份、乌梅10~20份、牡蛎10~20份、山楂10~20份、白芍10~20份、半枝莲5~15份、乌药5~15份、三七5~15份、川楝子10~20份、延胡索10~20份、旋覆花10~20份、藕节10~20份、白及5~15份、黄芩10~20份、山药10~20份、甘草20~30份。本发明将中药材微粉化,克服了普通粉碎技术制备的中药散剂粒度不均一、因粉碎问题导致纤维性药材比例不准确、因普通粉碎过程中温度升高而影响热不稳定药材的生物活性成分等缺点。
The invention relates to a traditional Chinese medicine for treating chronic gastritis and a preparation method of micronized granules. It is characterized in that it is composed of 20-30 parts by weight of lizards, 10-20 parts of ebony, 10-20 parts of oysters, 10-20 parts of hawthorn, 10-20 parts of white peony root, 5-15 parts of bark lotus, 5-15 parts of black medicine, 5-15 parts of Panax notoginseng, 10-20 parts of Sichuan neem, 10-20 parts of Corydalis, 10-20 parts of Inula, 10-20 parts of lotus root, 5-15 parts of Baiji, 10-20 parts of skullcap, 10-20 parts of yam, 20-30 parts of licorice. The method micronizes the traditional Chinese medicinal materials, and overcomes the uneven particle size of the traditional Chinese medicinal powder prepared by the ordinary pulverization technology, the inaccurate proportion of the fibrous medicinal materials due to the pulverization problem, and the influence of the temperature increase in the ordinary pulverization process. The bioactive components of the thermally unstable medicinal materials are affected and other shortcomings.
Description
技术领域technical field
本发明涉及一种治疗慢性胃炎的中药及其微粉化颗粒的制备方法。The invention relates to a traditional Chinese medicine for treating chronic gastritis and a preparation method of micronized granules.
背景技术Background technique
中医认为慢性胃炎可由饮食不节、情绪内伤、外感六邪等因素导致。基于叶天士“久病入络”理论认识,认为湿、热、痰、瘀等浊毒客结胃膜,阻滞胃肠气血运行,使其血败肉腐,化腐为脓,损伤胃肠黏膜。故本发明参合“内疡”“内痈”的治疗方法,提出护膜愈疮,保护修复胃黏膜治本之法。Traditional Chinese medicine believes that chronic gastritis can be caused by factors such as improper diet, internal emotional injury, and six external factors. Based on Ye Tianshi's theoretical understanding of "long-term illness enters the collaterals", it is believed that dampness, heat, phlegm, blood stasis and other turbid toxins bind the gastric membrane, block the circulation of qi and blood in the gastrointestinal tract, make the blood and flesh rot, turn the rot into pus, and damage the gastrointestinal tract. mucosa. Therefore, the present invention is combined with the treatment methods of "internal ulcer" and "internal carbuncle", and proposes a method of protecting and repairing the gastric mucosa to cure the sore by protecting the membrane.
本发明用于治疗慢性胃炎的中药方剂由蜥蜴、乌梅、牡蛎、山楂、白芍、半枝莲、乌药、三七、川楝子、延胡索、旋覆花、藕节、白及、黄芩、山药和甘草组成。方剂中蜥蜴具有破结散瘀、养血活血、清热解毒之效,可有效改善胃腑气血亏损、脉络苦涩,促进胃粘膜修复;乌梅、山楂、白芍等药酸甘敛阴,养阴止痛,上能敛肺气,下能涩大肠,入胃又能生津、安蛔;牡蛎平肝潜阳,软坚散结,收敛固涩;半枝莲清热解毒、活血化瘀,协助蜥蜴以祛邪;乌药味辛行散、性温祛寒,具有行气开郁、散寒止痛之效,且对胃肠道平滑肌有兴奋和抑制的双向调节作用;三七活血养血,改善胃黏膜微循环;川楝子行气开郁,理气止痛;延胡索、炒藕节、白及等药活血消肿,增强消肿散结,促进胃黏膜的修复;黄芩清热解毒,配合蜥蜴加强其解毒和修复的作用;旋覆花疏肝泄热、和胃降逆;白及含有胶质和淀粉等成分,具有收敛生肌、消肿止血、抗病原微生物、调节免疫以及促进组织愈合等作用;山药含薯蓣皂苷元、粘液质、胆碱、淀粉、糖蛋白、游离氨基酸、止杈素、维生素C和淀粉酶等,营养丰富、容易消化,具有补脾肺肾气、益脾肺肾阴的功效;甘草可补脾胃中气、缓急止痛;诸药合用修复受损胃黏膜,改善溃疡面血液循环,增强其营养,促进疡面得愈,用于有效治疗慢性胃炎。The traditional Chinese medicine prescription for treating chronic gastritis is composed of lizard, black plum, oyster, hawthorn, white peony, bark lotus, black medicine, Panax notoginseng, Sichuan neem, Corydalis, inula flower, lotus root, Baiji, Scutellaria baicalensis, Composition with yam and licorice. Lizard in the prescription has the effects of breaking knots and dissipating blood stasis, nourishing blood and promoting blood circulation, clearing heat and detoxifying, which can effectively improve the loss of qi and blood in the stomach, the bitterness of the veins, and promote the repair of gastric mucosa. Pain-relieving, upper can restrain lung qi, lower can astringe the large intestine, enter the stomach and can also promote body fluid and calm ascaris; oyster calms the liver and subdues yang, softens and dissipates stagnation, astringent and astringent; Banzhilian clears heat and detoxifies, promotes blood circulation and removes blood stasis, and assists lizards to dispel Evil; Wuyao Weixin Xingsan, warm in nature and dispelling cold, has the effect of invigorating qi, dispelling cold and relieving pain, and has a two-way regulation effect of excitation and inhibition on gastrointestinal smooth muscle; Panax notoginseng promotes blood and nourishes blood, improves gastric mucosal micro-organisms. Circulation; Chuan Neem promotes Qi, regulates Qi and relieves pain; Corydalis, fried lotus root, Baiji and other medicines promote blood circulation and reduce swelling, enhance swelling and dissipate knots, and promote the repair of gastric mucosa; Scutellaria baicalensis clears heat and detoxifies, and cooperates with lizards to strengthen its detoxification and repair Inula vulgaris has the functions of soothing the liver and expelling heat, and relieving the stomach and lowering the negative effect; Baiji contains colloid and starch and other components, which have the functions of astringing and promoting muscle, reducing swelling and hemostasis, resisting pathogenic microorganisms, regulating immunity, and promoting tissue healing; Chinese yam Contains diosgenin, mucilage, choline, starch, glycoproteins, free amino acids, teratin, vitamin C and amylase, etc. It is nutritious and easy to digest. Licorice can replenish spleen and stomach qi, relieve acute pain and relieve pain; the combination of various medicines can repair damaged gastric mucosa, improve blood circulation on ulcers, enhance its nutrition, and promote healing of ulcers, and is used to effectively treat chronic gastritis.
目前本中药方剂用于治疗慢性胃炎的剂型为散剂,在临床试验137例中,随机分为治疗组69例和对照组68例,治疗组采用本中药方剂散剂治疗,6g/次,加3g纯藕粉,用开水调成糊状,饭后2h服用,3次/日;对照组口服胃复春片,每次4片,3次/日,12周为一个疗程。疗程结束后比较两组患者的临床疗效情况,并观察其安全性及不良反应。临床疗效情况如表1-3所示,治疗组总有效率为89.86%,对照组总有效率为69.12%,且治疗组可以改善慢性胃炎黏膜萎缩、杀灭幽门螺杆菌(HP),远期疗效好。两组患者治疗结束后复查血、尿、大便常规及心、肝、肾功能均未发现异常改变,无不良反应。临床试验表明该中药方剂可有效治疗慢性胃炎,且安全性好,但是该散剂采用普通粉碎技术制备,粒度不均一,且在普通粉碎过程中会产生过热现象,一些对热不稳定的中药材有效成分可能会受到影响;同时,纤维成分丰富的药材采用普通粉碎机粉碎后不易过筛,经多次粉碎后仍不能过筛的被当作杂质扔掉,导致处方中纤维成分丰富的药材用量不准确,影响药效的发挥。因此,值得研究开发出粒度均一、药材比例更准确、疗效更好的中药制剂产品。At present, the dosage form of this traditional Chinese medicine formula for the treatment of chronic gastritis is powder. In the clinical trial, 137 cases were randomly divided into a treatment group of 69 cases and a control group of 68 cases. Lotus root starch was made into a paste with boiled water, taken 2 hours after meals, 3 times a day; the control group was orally taken Weifuchun tablets, 4 tablets each time, 3 times a day, 12 weeks as a course of treatment. After the course of treatment, the clinical efficacy of the two groups of patients was compared, and their safety and adverse reactions were observed. The clinical efficacy is shown in Table 1-3, the total effective rate of the treatment group is 89.86%, and the total effective rate of the control group is 69.12%, and the treatment group can improve chronic gastritis mucosal atrophy, kill Helicobacter pylori (HP), and in the long-term. Good curative effect. No abnormal changes were found in the blood, urine, stool routines, heart, liver and kidney functions of the two groups of patients after treatment, and no adverse reactions were found. Clinical trials have shown that the traditional Chinese medicine formula can effectively treat chronic gastritis and has good safety. However, the powder is prepared by ordinary pulverization technology, the particle size is not uniform, and overheating will occur during the ordinary pulverization process, and some Chinese medicinal materials that are thermally unstable are effective. The ingredients may be affected; at the same time, the medicinal materials rich in fiber components are not easy to pass through the sieve after being crushed by ordinary pulverizers, and those that cannot be sieved after being crushed for many times are thrown away as impurities, resulting in insufficient dosage of medicinal materials rich in fiber components in the prescription. Accurate, affecting the efficacy of the drug. Therefore, it is worth researching and developing traditional Chinese medicine preparation products with uniform particle size, more accurate proportion of medicinal materials and better curative effect.
表1两组间临床疗效比较表Table 1 Comparison of clinical efficacy between the two groups
表2两组间改善胃黏膜病理情况比较表Table 2 Comparison of the improvement of gastric mucosa pathological conditions between the two groups
表3两组间抗HP感染疗效比较表Table 3 Comparison of the efficacy of anti-HP infection between the two groups
发明内容SUMMARY OF THE INVENTION
本发明的目的之一是提供一种治疗慢性胃炎的中药,参合“内疡”“内痈”的治疗方法,采用护膜愈疮、保护修复胃黏膜治本之法治疗慢性胃炎;One of the objects of the present invention is to provide a kind of traditional Chinese medicine for the treatment of chronic gastritis, and the treatment methods of "internal ulcer" and "internal carbuncle" are used for the treatment of chronic gastritis by using the method of protecting and repairing the ulcer and protecting and repairing the gastric mucosa;
本发明的目的之二是以提供一种上述中药微粉化颗粒的制备方法,能够增加了中药的稳定性和防潮性,有利于贮藏。The second purpose of the present invention is to provide a preparation method of the above-mentioned traditional Chinese medicine micronized particles, which can increase the stability and moisture resistance of the traditional Chinese medicine, and is beneficial to storage.
一种治疗慢性胃炎的中药,其特别之处在于,按照重量份计组成为:蜥蜴20~30份、乌梅10~20份、牡蛎10~20份、山楂10~20份、白芍10~20份、半枝莲5~15份、乌药5~15份、三七5~15份、川楝子10~20份、延胡索10~20份、旋覆花10~20份、藕节10~20份、白及5~15份、黄芩10~20份、山药10~20份、甘草20~30份。A traditional Chinese medicine for treating chronic gastritis, which is special in that it is composed of 20-30 parts by weight of lizard, 10-20 parts of ebony, 10-20 parts of oyster, 10-20 parts of hawthorn, 10-20 parts of white peony root 5-15 parts of Banzhilian, 5-15 parts of black medicine, 5-15 parts of Panax notoginseng, 10-20 parts of Sichuan neem, 10-20 parts of Corydalis, 10-20 parts of Inula flower, 10-20 parts of
一种治疗慢性胃炎的中药微粉化颗粒的制备方法,其特别之处在于,包括如下步骤:A preparation method of traditional Chinese medicine micronized granules for the treatment of chronic gastritis, which is special in that it comprises the following steps:
(1)清洗:按照权利要求1中记载的配比取所有中药材,用纯化水进行快速清洗,待水分挥干后喷洒75%酒精静置;(1) cleaning: get all the Chinese medicinal materials according to the proportioning recorded in claim 1, carry out quick cleaning with purified water, spray 75% alcohol to stand after the water is evaporated to dryness;
(2)干燥:将得到的中药材进行干燥处理,控制干燥温度为50~90℃,干燥至含水量为3%~8%;(2) Drying: drying the obtained Chinese medicinal materials, controlling the drying temperature to be 50-90°C, and drying to a moisture content of 3%-8%;
(3)粗粉碎:将得到的干燥药材粉碎,得到中药材粗粉;(3) Coarse pulverization: pulverize the obtained dried medicinal materials to obtain coarse powder of Chinese medicinal materials;
(4)微粉化:将得的中药材粗粉进行超微粉碎,得到中药材微粉;(4) Micronization: the obtained Chinese medicinal material coarse powder is ultrafinely pulverized to obtain Chinese medicinal material micropowder;
(5)制粒:将得到的中药材微粉进行制粒,得到12~24目的中药微粉化颗粒;(5) granulation: granulating the obtained Chinese medicinal material micropowder to obtain 12-24 mesh Chinese medicinal micronized granules;
(6)分量包装即可。(6) The quantity can be packaged.
步骤(4)中微粉化具体采用低温振动式超微粉碎机或者气流式超微粉碎机,其中采用低温振动式超微粉碎机粉碎时,控制粉碎温度为-50~-20℃,粉碎时间为5~20min;其中采用气流式超微粉碎机粉碎时,控制气流压强0.5~1.5MPa,进料速度1~1.5kg/h,粉碎温度为-20~-10℃,粉碎时间为5~20min。In step (4), a low-temperature vibration type ultra-fine pulverizer or an air-flow type ultra-fine pulverizer is specifically used for the micronization, and when the low-temperature vibration type ultra-fine pulverizer is used for pulverization, the pulverization temperature is controlled to be -50 to -20° C., and the pulverization time is 5~20min; when the air flow type ultrafine pulverizer is used for pulverization, the air pressure is controlled to 0.5~1.5MPa, the feed rate is 1~1.5kg/h, the pulverization temperature is -20~-10℃, and the pulverization time is 5~20min.
步骤(5)中制粒具体采用湿法制粒或者干法制粒,其中采用湿法制粒时,在中药材微粉中喷入30%~90%体积分数的乙醇,并搅拌均匀制软材,以12~24目筛网制粒,然后进行干燥处理,控制干燥温度为30~70℃,干燥至饮片含水量为3%~8%,过12~24目筛整粒;其中采用干法制粒时,将中药材微粉直接加入颗粒机,控制挤压压力为10~20MPa,挤压速度为15~25r/min,送料速度为20~30r/min,制得粒径为12~24目的颗粒。5、如权利要求2所述的一种治疗慢性胃炎的中药微粉化颗粒的制备方法,其特征在于:步骤(6)分量包装具体是将中药微粉化颗粒用铝塑膜包装袋分装,每袋含微粉化颗粒3~6g。The granulation in step (5) specifically adopts wet granulation or dry granulation. When wet granulation is adopted, 30% to 90% volume fraction of ethanol is sprayed into the micropowder of the traditional Chinese medicinal material, and the soft material is prepared by stirring uniformly. 24-mesh sieve for granulation, then drying, controlling the drying temperature to be 30-70°C, drying until the moisture content of the decoction pieces is 3%-8%, and passing through a 12-24 mesh sieve for granulation; when dry granulation is used, The Chinese medicinal material micropowder is directly added to the granulator, and the extrusion pressure is controlled to be 10-20 MPa, the extrusion speed is 15-25 r/min, and the feeding speed is 20-30 r/min, so that the particle size is 12-24 meshes. 5. The method for preparing micronized granules of traditional Chinese medicine for the treatment of chronic gastritis as claimed in claim 2, characterized in that: in step (6), the component packaging is specifically that the micronized granules of traditional Chinese medicine are divided into aluminum-plastic film packaging bags, and each The bag contains 3 to 6 g of micronized particles.
本发明将中药材微粉化,克服了普通粉碎技术制备的中药散剂粒度不均一、因粉碎问题导致纤维性药材比例不准确、因普通粉碎过程中温度升高而影响热不稳定药材的生物活性成分等缺点。本发明再将中药材微粉采用制粒技术制成颗粒,克服了微粉化中药因粒度极细导致流动性差、不方便包装等缺点,同时增加了中药的稳定性和防潮性,有利于贮藏。本发明的中药微粉化颗粒,参合“内疡”“内痈”的治疗方法,采用护膜愈疮、保护修复胃黏膜治本之法治疗慢性胃炎,利用君药蜥蜴有再生和修复人类损伤组织功能、增强人体免疫功能,利用黏性药物使药黏附于胃黏膜表面而直接作用于病灶,最终促进增生、肠化的胃黏膜细胞凋亡,帮助黏膜的再生修复,且中药微粉化后比表面积的增大更有利于中药成分的溶出发挥疗效,具有健脾养胃、补虚强壮的功效,疗效好、治愈率高、无不良反应。The method micronizes the traditional Chinese medicinal materials, and overcomes the uneven particle size of the traditional Chinese medicinal powder prepared by the ordinary pulverization technology, the inaccurate proportion of the fibrous medicinal materials due to the pulverization problem, and the influence of the temperature increase in the ordinary pulverization process. The bioactive components of the thermally unstable medicinal materials are affected and other shortcomings. In the present invention, the micropowder of traditional Chinese medicinal materials is made into granules by granulation technology, which overcomes the disadvantages of poor fluidity and inconvenient packaging of the micronized traditional Chinese medicine due to the extremely fine particle size, and at the same time increases the stability and moisture resistance of the traditional Chinese medicine, which is beneficial to storage. The traditional Chinese medicine micronized granules of the present invention are combined with the treatment methods of "internal ulcer" and "internal carbuncle", adopt the method of protecting the membrane to heal the sore, protecting and repairing the gastric mucosa to cure chronic gastritis, and using the monarch medicine lizard has the function of regenerating and repairing human damaged tissue , Enhance the immune function of the human body, use viscous drugs to make the drugs adhere to the surface of the gastric mucosa and directly act on the lesions, and finally promote the apoptosis of gastric mucosal cells that proliferate and enter the intestines, and help the regeneration and repair of the mucosa. Enlargement is more conducive to the dissolution of traditional Chinese medicine ingredients to exert the curative effect, has the effects of invigorating the spleen, nourishing the stomach, invigorating deficiency and strengthening, good curative effect, high cure rate, and no adverse reactions.
附图说明Description of drawings
图1为中药材微粉的临界相对湿度曲线;Fig. 1 is the critical relative humidity curve of Chinese herbal medicine micropowder;
图2为本发明制备的中药微粉化颗粒的外观均匀度图。Fig. 2 is the appearance uniformity diagram of the micronized particles of traditional Chinese medicine prepared by the present invention.
具体实施方式Detailed ways
本发明保护一种治疗慢性胃炎的中药微粉化颗粒及其制备方法,该颗粒由蜥蜴、乌梅、牡蛎、山楂、白芍、半枝莲、乌药、三七、川楝子、延胡索、旋覆花、藕节、白及、黄芩、山药和甘草共十六味中药饮片制备而成。本中药方剂在临床上治疗慢性胃炎用滚开水调成糊状口服,6g/次,3次/d,餐后2h服用,服药后2h内禁饮食,以使药物粘附在胃黏膜表面,有效控制肠液和胆汁反流,达到通降气机、和胃健运、修复胃黏膜的目的。每用中药糊剂一至两个疗程,并嘱患者调情志、节饮食、慎起居,“缓缓图之”,患者多获痊愈。即有个别患者因饮食不当或七情失节等而复发,症情亦较轻,续服中药糊剂即可恢复。本发明所述中药微粉化颗粒的制备方法为将干燥后的药材采用万能粉碎机粉碎为粗粉,将粗粉采用超微粉碎技术进行药物微粉化,再采用制粒技术制备成微粉化颗粒。本发明将中药材微粉化,克服了普通粉碎技术制备的中药散剂粒度不均一、因粉碎问题导致纤维性药材比例不准确、因普通粉碎过程中温度升高而影响热不稳定药材的生物活性成分等缺点。The present invention protects a traditional Chinese medicine micronized granule for treating chronic gastritis and a preparation method thereof. It is prepared from sixteen Chinese herbal decoction pieces of flowers, lotus root, Baiji, skullcap, yam and licorice. In clinical treatment of chronic gastritis, this traditional Chinese medicine formula is used to make a paste with boiling water and take it orally. Control the reflux of intestinal juice and bile, achieve the purpose of ventilating and lowering the air, and the stomach, and repairing the gastric mucosa. Each time one or two courses of traditional Chinese medicine paste are used, and the patients are instructed to flirt, eat less, and live with caution. That is to say, some patients relapse due to improper diet or disorder of seven emotions, etc., and the symptoms are relatively mild, and they can be recovered by continuing to take the traditional Chinese medicine paste. The preparation method of the traditional Chinese medicine micronized granules of the present invention is to pulverize the dried medicinal materials into coarse powder by using a universal pulverizer, use the ultra-fine pulverization technology to micronize the coarse powder, and then use the granulation technology to prepare the micronized granules. The method micronizes the traditional Chinese medicinal materials, and overcomes the uneven particle size of the traditional Chinese medicinal powder prepared by the ordinary pulverization technology, the inaccurate proportion of the fibrous medicinal materials due to the pulverization problem, and the influence of the temperature increase in the ordinary pulverization process. The bioactive components of the thermally unstable medicinal materials are affected and other shortcomings.
本发明再将中药材微粉采用制粒技术制成颗粒,克服了微粉化中药因粒度极细导致流动性差、不方便包装等缺点,同时增加了中药的稳定性和防潮性,有利于贮藏。本发明的中药微粉化颗粒,利用君药蜥蜴的增强机体免疫、修复受损组织功能,利用黏性药物使药黏附于胃黏膜表面而直接作用于病灶,且中药微粉化后比表面积的增大更有利于中药成分的溶出发挥疗效,因此具有健脾养胃、补虚强壮的功效,疗效好、治愈率高、无不良反应。In the present invention, the micropowder of traditional Chinese medicinal materials is made into granules by granulation technology, which overcomes the disadvantages of poor fluidity and inconvenient packaging of the micronized traditional Chinese medicine due to the extremely fine particle size, and at the same time increases the stability and moisture resistance of the traditional Chinese medicine, which is beneficial to storage. The micronized granules of the traditional Chinese medicine of the present invention utilize the functions of the monarch drug lizard to enhance the body's immunity and repair damaged tissues, use the viscous drug to make the drug adhere to the surface of the gastric mucosa and directly act on the lesions, and the specific surface area increases after the traditional Chinese medicine is micronized It is more conducive to the dissolution of traditional Chinese medicine ingredients to exert the curative effect, so it has the effects of invigorating the spleen, nourishing the stomach, invigorating deficiency and strengthening, with good curative effect, high cure rate and no adverse reactions.
本发明针对上述中药散剂及现有制剂技术的缺陷,提供一种用于治疗慢性胃炎的中药微粉化颗粒及其制备方法。本发明采用超微粉碎技术将中药材进行微粉化,可以克服普通粉碎技术制备的散剂粒度不均一、纤维性药材比例不准确的缺点,并采用低温粉碎解决因普通粉碎过程中温度升高而影响热不稳定药材的有效成分的问题。但同时中药材微粉由于粒度极细导致流动性差、不方便包装,比表面积的增大使药物的吸湿性相应增大,本发明采用制粒技术进一步对中药材微粉进行制粒,以改善制剂的吸湿性和流动性。Aiming at the defects of the above-mentioned traditional Chinese medicine powder and the existing preparation technology, the present invention provides a traditional Chinese medicine micronized granule for treating chronic gastritis and a preparation method thereof. The invention adopts the ultra-fine pulverization technology to micronize the traditional Chinese medicinal materials, which can overcome the disadvantages of uneven particle size and inaccurate proportion of the fibrous medicinal materials prepared by the ordinary pulverization technology, and adopts low-temperature pulverization to solve the problems caused by the temperature increase in the ordinary pulverization process. The problem of active ingredients of heat-labile herbs. However, at the same time, the micro-powder of Chinese medicinal materials has poor fluidity and is inconvenient for packaging due to its extremely fine particle size, and the increase in specific surface area increases the hygroscopicity of the drug accordingly. Sex and mobility.
为实现上述目的,本发明采取的技术方案为:一种用于治疗慢性胃炎的中药微粉化颗粒,所述各中药组份按以下重量份配比组成:蜥蜴20~30份、乌梅10~20份、牡蛎10~20份、山楂10~20份、白芍10~20份、半枝莲5~15份、乌药5~15份、三七5~15份、川楝子10~20份、延胡索10~20份、旋覆花10~20份、藕节10~20份、白及5~15份、黄芩10~20份、山药10~20份、甘草20~30份。In order to achieve the above purpose, the technical scheme adopted in the present invention is: a kind of traditional Chinese medicine micronized granules for the treatment of chronic gastritis, wherein each traditional Chinese medicine component is composed of the following parts by weight: 20-30 parts of lizard, 10-20 parts of ebony servings, 10-20 servings of oysters, 10-20 servings of hawthorn, 10-20 servings of white peony root, 5-15 servings of Banzhilian, 5-15 servings of black medicine, 5-15 servings of Panax notoginseng, 10-20 servings of Sichuan neem , 10-20 copies of Corydalis, 10-20 copies of Inula, 10-20 copies of lotus root, 5-15 copies of Baiji, 10-20 copies of skullcap, 10-20 copies of yam, and 20-30 copies of licorice.
一种用于治疗慢性胃炎的中药微粉化颗粒及其制备方法,步骤是:A traditional Chinese medicine micronized granule for treating chronic gastritis and a preparation method thereof, the steps are:
(1)清洗:将蜥蜴、乌梅、牡蛎、山楂、白芍、半枝莲、乌药、三七、川楝子、延胡索、旋覆花、藕节、白及、黄芩、山药和甘草用纯化水进行快速清洗,待水分挥干后喷洒75%酒精静置;(1) Cleaning: Purify lizard, black plum, oyster, hawthorn, white peony, bark lotus, black medicine, Panax notoginseng, Sichuan neem, Corydalis, inula flower, lotus root, Baiji, skullcap, yam and licorice Quickly clean with water, spray 75% alcohol after the water evaporates and let it stand;
(2)干燥:将中药材饮片放至电热恒温干燥箱进行干燥处理,干燥温度为50~90℃,干燥至饮片含水量为3%~8%;(2) Drying: put the Chinese herbal medicine pieces in an electric heating constant temperature drying oven for drying treatment, the drying temperature is 50~90℃, and the water content of the pieces is 3%~8%;
(3)粗粉碎:将步骤(2)所得的干燥药材,用万能粉碎机粉碎5~20min,得到中药材粗粉;(3) Coarse pulverization: pulverize the dried medicinal materials obtained in step (2) with a universal pulverizer for 5-20 min to obtain coarse powder of Chinese medicinal materials;
(4)微粉化:将步骤(3)所得的中药材粗粉,采用超微粉碎技术进行粉碎,得到中药材微粉;(4) Micronization: the coarse powder of Chinese medicinal materials obtained in step (3) is pulverized by ultrafine pulverization technology to obtain micropowder of Chinese medicinal materials;
(5)制粒:采用制粒技术将步骤(4)所得中药材微粉采用制粒技术进行制粒,得到12~24目的中药微粉化颗粒。(5) granulation: using the granulation technology to granulate the Chinese medicinal material micropowder obtained in the step (4) by the granulation technology, to obtain 12-24 mesh Chinese medicine micronized granules.
(6)分量包装:将中药微粉化颗粒用铝塑膜包装袋分装,每袋含微粉化颗粒重量为3~6g。(6) Quantity packaging: The micronized particles of traditional Chinese medicine are packaged in aluminum-plastic film packaging bags, and each bag contains 3-6g of micronized particles.
作为本发明所述中药微粉化颗粒的制备方法的优选实施方式,所述步骤(4)中微粉化可采用低温振动式超微粉碎机和气流式超微粉碎机制备,其中,采用低温振动式超微粉碎机粉碎时,粉碎温度为-50~-20℃,粉碎时间为5~20min;采用气流式超微粉碎机粉碎时,气流压强0.5~1.5MPa,进料速度1~1.5kg/h,粉碎温度为-20~-10℃,粉碎时间为5~20min。As a preferred embodiment of the method for preparing micronized particles of traditional Chinese medicine according to the present invention, in the step (4), the micronization can be prepared by using a low-temperature vibration type ultra-fine pulverizer and an air-flow type ultra-fine pulverizer, wherein the low-temperature vibration type When pulverizing with an ultrafine pulverizer, the pulverization temperature is -50~-20℃, and the pulverization time is 5~20min; when pulverizing by an air flow ultrafine pulverizer, the air pressure is 0.5~1.5MPa, and the feeding speed is 1~1.5kg/h , the pulverization temperature is -20~-10℃, and the pulverization time is 5~20min.
作为本发明所述中药微粉化颗粒的制备方法的优选实施方式,所述步骤(5)中制粒过程可采用湿法制粒和干法制粒,其中,湿法制粒时,在中药材微粉中加入30%~90%体积分数的乙醇,并搅拌均匀制软材,以12~24目筛网制粒,放至电热恒温干燥箱进行干燥处理,干燥温度为30~70℃,干燥至饮片含水量为3%~8%,过12~24目筛整粒;干法制粒时,将中药材微粉直接加入颗粒机,挤压压力为10~20MPa,挤压速度为15~25r/min,送料速度为20~30r/min,制得粒径为12~24目的颗粒。As a preferred embodiment of the method for preparing micronized granules of traditional Chinese medicine according to the present invention, wet granulation and dry granulation can be used in the granulation process in the step (5). 30% to 90% ethanol by volume, and stir evenly to make soft material, granulate with 12 to 24 mesh sieves, and put them in an electric heating constant temperature drying oven for drying treatment. 3%~8%, pass through 12~24 mesh sieves for granulation; during dry granulation, add Chinese medicinal powder directly into the granulator, the extrusion pressure is 10~20MPa, the extrusion speed is 15~25r/min, and the feeding speed is It is 20~30r/min, and the particle size is 12~24 meshes.
为更好的说明本发明的目的、技术方案和优点,下面将结合具体实施例对本发明作进一步说明。In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below with reference to specific embodiments.
实施例1:Example 1:
(一)一种治疗慢性胃炎的中药微粉化颗粒,由以下中药材按重量份配比而成:蜥蜴20份、乌梅10份、牡蛎10份、山楂10份、白芍10份、半枝莲5份、乌药5份、三七5份、川楝子10份、延胡索10份、旋覆花10份、藕节10份、白及5份、黄芩10份、山药10份、甘草20份。(1) A kind of traditional Chinese medicine micronized granules for the treatment of chronic gastritis, composed of the following Chinese medicinal materials in proportion by weight: 20 parts of lizard, 10 parts of black plum, 10 parts of oyster, 10 parts of hawthorn, 10 parts of white peony root, 10 parts of bark lotus 5 parts, 5 parts of black medicine, 5 parts of Panax notoginseng, 10 parts of Sichuan neem, 10 parts of Corydalis, 10 parts of Inula flower, 10 parts of lotus root, 5 parts of Baiji, 10 parts of skullcap, 10 parts of yam, 20 parts of licorice .
(二)制备方法:(2) Preparation method:
按重量称取将蜥蜴、乌梅、牡蛎、山楂、白芍、半枝莲、乌药、三七、川楝子、延胡索、旋覆花、藕节、白及、黄芩、山药和甘草各组份,用纯化水进行快速清洗,待水分挥干后喷洒75%酒精静置,待酒精挥发完后放至50℃的电热恒温干燥箱中,干燥至含水量为3%,在洁净间用万能粉碎机粉碎5min,得到粗粉,再用低温振动式粉碎机进行粉碎5min,粉碎温度为-30℃,得到中药材微粉。加入30%的乙醇制软材,以12目筛网制粒,放至50℃的电热恒温干燥箱中进行干燥处理,过12目筛整粒,得到微粉化颗粒。将合格的微粉化颗粒Weigh the components of lizard, black plum, oyster, hawthorn, white peony, bark lotus, black medicine, Panax notoginseng, Sichuan neem, Corydalis, inula flower, lotus root, Baiji, skullcap, yam and licorice by weight. , use purified water for quick cleaning, spray 75% alcohol after the water evaporates, and leave it to stand. After the alcohol evaporates, put it in an electric heating constant temperature drying box at 50 °C, dry to a water content of 3%, and use a universal pulverizer in the clean room. Machine pulverized for 5 min to obtain coarse powder, and then pulverized with a low-temperature vibrating pulverizer for 5 min at a pulverization temperature of -30° C. to obtain micropowder of Chinese medicinal materials. Add 30% ethanol to make soft material, granulate with a 12-mesh sieve, put it into an electric heating constant temperature drying oven at 50° C. for drying treatment, pass through a 12-mesh sieve for granulation, and obtain micronized granules. Qualified micronized particles
用铝塑袋分装,控制分装室的温度为19℃,相对湿度为40%,按规格进行分装及外包装,每袋含微粉化颗粒3g。Use aluminum-plastic bags for packaging, control the temperature of the packaging room to be 19 ° C, and the relative humidity to be 40%. The packaging and outer packaging are carried out according to the specifications. Each bag contains 3g of micronized particles.
表4中药材微粉的质量检查Table 4 Quality inspection of Chinese herbal medicine micropowder
表5中药微粉化颗粒的质量检查Table 5 Quality inspection of micronized granules of traditional Chinese medicine
表4是对本发明制备的中药材微粉进行了质量检查,结果中药材粗粉的出粉率为99.65%,65目的过筛率为78.71%,中药材微粉的出粉率为98.32%,200目的过筛率为95.50%,且粒径分布均匀。但中药材微粉的休止角较大,结合堆密度和振实密度结果,可进一步认为其流动性较差,这可能是由于粒度极小而导致的。通过测定吸湿平衡时间和临界相对湿度,考察了中药材微粉的吸湿性。吸湿平衡时间结果显示,中药材微粉的引湿增重小于15%但不小于2%,表明有引湿性,且吸湿平衡时间为4h。临界相对湿度结果如图1所示,中药材微粉的CRH约为57%,因此中药材微粉的贮存及制粒环境应控制在57%以下。表5展示了本发明制备的中药微粉化颗粒的质量检查结果,结果显示,该制备工艺下的颗粒成品率较高;按照《中国药典》2015版颗粒剂项下规定进行粒度检查,结果不能通过一号筛与能通过五号筛的总和为0.15%,符合规定;从休止角、堆密度、振实密度结果可以看出,将中药材微粉制备成颗粒之后明显改善了其流动性。同时考察了中药微粉化颗粒的外观均匀度,结果如图2所示,将中药微粉化颗粒平铺在光滑纸上,观察到色泽均匀。Table 4 shows the quality inspection of the micro-powder of Chinese medicinal materials prepared by the present invention. As a result, the yield of the coarse powder of Chinese medicinal materials is 99.65%, the sieving rate of 65 meshes is 78.71%, and the yield of micro-powders of Chinese medicinal materials is 98.32%, and the yield of 200 meshes is 98.32%. The sieving rate was 95.50%, and the particle size distribution was uniform. However, the angle of repose of the micropowder of Chinese medicinal materials is relatively large. Combined with the results of bulk density and tap density, it can be further considered that its fluidity is poor, which may be caused by the extremely small particle size. The hygroscopicity of Chinese herbal medicine micropowder was investigated by measuring the hygroscopic equilibrium time and critical relative humidity. The results of hygroscopic equilibrium time showed that the moisture-inducing weight gain of Chinese herbal medicine micropowder was less than 15% but not less than 2%, indicating that it had hygroscopicity, and the hygroscopic equilibrium time was 4h. The results of the critical relative humidity are shown in Figure 1. The CRH of the Chinese herbal medicine micropowder is about 57%, so the storage and granulation environment of the Chinese herbal medicine micropowder should be controlled below 57%. Table 5 shows the quality inspection results of the traditional Chinese medicine micronized granules prepared by the present invention. The results show that the granule yield under this preparation process is relatively high; the particle size inspection is carried out according to the provisions of the "Chinese Pharmacopoeia" 2015 edition granules, and the result cannot pass The sum of No. 1 sieve and No. 5 sieve is 0.15%, which is in line with the regulations. From the results of angle of repose, bulk density and tap density, it can be seen that the fluidity of Chinese medicinal powder is obviously improved after being prepared into granules. At the same time, the appearance uniformity of the micronized particles of traditional Chinese medicine was investigated. The results are shown in Figure 2. The micronized particles of traditional Chinese medicine were spread on smooth paper, and it was observed that the color was uniform.
实施例2:Example 2:
(一)一种治疗慢性胃炎的中药材微粉化颗粒,由以下中药材按重量份配比而成:蜥蜴25份、乌梅15份、牡蛎15份、山楂15份、白芍15份、半枝莲10份、乌药10份、三七10份、川楝子15份、延胡索15份、旋覆花15份、藕节15份、白及10份、黄芩15份、山药15份、甘草25份。(1) A micronized granule of Chinese medicinal materials for treating chronic gastritis, which is composed of the following Chinese medicinal materials by weight: 25 parts of lizard, 15 parts of black plum, 15 parts of oyster, 15 parts of hawthorn, 15 parts of white peony root, 10 parts of lotus, 10 parts of black medicine, 10 parts of Panax notoginseng, 15 parts of Sichuan neem, 15 parts of Corydalis, 15 parts of Inula flower, 15 parts of lotus root, 10 parts of Baiji, 15 parts of skullcap, 15 parts of yam, 25 parts of licorice share.
(二)制备方法:(2) Preparation method:
按重量称取将蜥蜴、乌梅、牡蛎、山楂、白芍、半枝莲、乌药、三七、川楝子、延胡索、旋覆花、藕节、白及、黄芩、山药和甘草各组份,用纯化水进行快速清洗,待水分挥干后喷洒75%酒精静置,待酒精挥发完后放至70℃的电热恒温干燥箱中,干燥至含水量为5%,在洁净间用万能粉碎机粉碎10min,得到粗粉,再用低温振动式粉碎机进行粉碎,粉碎温度为-20℃,粉碎时间设定为5min,得到中药材微粉。加入60%的乙醇制软材,以18目筛网制粒,放至70℃的电热恒温干燥箱中进行干燥处理,过18目筛整粒,得到微粉化颗粒。将合格的微粉化颗粒用铝塑袋分装,控制分装室的温度为25℃,相对湿度为50%,按规格进行分装及外包装,每袋含微粉化颗粒4g。Weigh the components of lizard, black plum, oyster, hawthorn, white peony, bark lotus, black medicine, Panax notoginseng, Sichuan neem, Corydalis, inula flower, lotus root, Baiji, skullcap, yam and licorice by weight. , use purified water for quick cleaning, spray 75% alcohol after the water evaporates, and leave it to stand. After the alcohol evaporates, put it in an electric heating constant temperature drying box at 70 °C, dry it to a water content of 5%, and use it in the clean room. Pulverized by machine for 10 min to obtain coarse powder, and then pulverized with a low-temperature vibrating pulverizer at a pulverization temperature of -20° C. and a pulverization time of 5 min to obtain micropowder of Chinese medicinal materials. Add 60% ethanol to make soft material, granulate with 18-mesh sieve, put it into an electric heating constant temperature drying oven at 70° C. for drying treatment, pass through an 18-mesh sieve for granulation, and obtain micronized granules. The qualified micronized particles are packaged in aluminum-plastic bags, the temperature of the packaging room is controlled to be 25°C, the relative humidity is 50%, and the packaging and outer packaging are carried out according to the specifications. Each bag contains 4g of micronized particles.
实施例3:Example 3:
(一)一种治疗慢性胃炎的中药材微粉化颗粒,由以下中药材按重量份配比而成:蜥蜴30份、乌梅20份、牡蛎20份、山楂20份、白芍20份、半枝莲15份、乌药15份、三七15份、川楝子20份、延胡索20份、旋覆花20份、藕节20份、白及15份、黄芩20份、山药20份、甘草30份。(1) A micronized granule of Chinese medicinal materials for treating chronic gastritis, which is composed of the following Chinese medicinal materials by weight: 30 parts of lizard, 20 parts of black plum, 20 parts of oyster, 20 parts of hawthorn, 20 parts of white peony root, 15 parts of lotus, 15 parts of black medicine, 15 parts of Panax notoginseng, 20 parts of Sichuan neem, 20 parts of Corydalis, 20 parts of Inula, 20 parts of lotus root, 15 parts of Baiji, 20 parts of skullcap, 20 parts of yam, 30 parts of licorice share.
(二)制备方法:(2) Preparation method:
按重量称取将蜥蜴、乌梅、牡蛎、山楂、白芍、半枝莲、乌药、三七、川楝子、延胡索、旋覆花、藕节、白及、黄芩、山药和甘草各组份,用纯化水进行快速清洗,待水分挥干后喷洒75%酒精静置,待酒精挥发完后放至90℃的电热恒温干燥箱中,干燥至含水量为8%,在洁净间用万能粉碎机粉碎20min,得到粗粉,再用气流式超微粉碎机进行粉碎,气流压强0.7MPa,进料速度1.2kg/h,粉碎时间为15min,得到中药材微粉,由颗粒机制粒,挤压压力为12MPa,挤压速度为21r/min,送料速度为26r/min,制得粒径为24目的颗粒。将合格的微粉化颗粒用铝塑袋分装,控制分装室的温度为28℃,相对湿度为55%,按规格进行分装及外包装,每袋含微粉化颗粒6g。Weigh the components of lizard, black plum, oyster, hawthorn, white peony, bark lotus, black medicine, Panax notoginseng, Sichuan neem, Corydalis, inula flower, lotus root, Baiji, skullcap, yam and licorice by weight. , use purified water for quick cleaning, spray 75% alcohol after the water evaporates, and leave it to stand. After the alcohol evaporates, put it in an electric heating constant temperature drying oven at 90 °C, dry to a water content of 8%, and use a universal pulverizer in the clean room. Pulverized by machine for 20min to obtain coarse powder, and then pulverized with an air flow ultrafine pulverizer. The air pressure is 0.7MPa, the feed rate is 1.2kg/h, and the pulverization time is 15min. is 12MPa, the extrusion speed is 21r/min, the feeding speed is 26r/min, and the particle size is 24 meshes. The qualified micronized particles are packaged in aluminum-plastic bags, and the temperature of the packaging room is controlled to be 28°C and the relative humidity is 55%, and the packaging and outer packaging are carried out according to the specifications. Each bag contains 6g of micronized particles.
实施例4:Example 4:
(一)药理试验方法(1) Pharmacological test methods
1.慢性胃炎模型制作1. Model making of chronic gastritis
150g/L、55℃热盐水,10mL/(kg·d),灌胃,3次/d;2%水杨酸溶液10mL/(kg·d)灌胃,1次/d;20mmoL/L脱氧胆酸钠溶液自由饮用,配合饥饱失常,即2天饱食,1天禁食,连续造模12周,形成慢性胃炎模型;分别在造模第4周、8周、12周末随机抽取各组大鼠一只,处死取胃,经病理组织学检查证实出现了明显的慢性胃炎病理特点,表示造模成功。150g/L, 55℃ hot saline, 10mL/(kg d), gavage, 3 times/d; 2% salicylic acid solution 10mL/(kg d) gavage, 1 time/d; 20mmol/L deoxygenation Sodium cholate solution was freely drank in combination with abnormal hunger and satiety, that is, 2 days of full food, 1 day of fasting, and continuous modeling for 12 weeks to form a chronic gastritis model. One rat in the group was sacrificed and its stomach was taken. The pathological features of chronic gastritis were confirmed by histopathological examination, indicating that the modeling was successful.
正常组大鼠经口灌胃0.9%的氯化钠溶液10mL/kg、2次/d,提供充足饮食及清洁自来水。The rats in the normal group were orally gavaged with 0.9% sodium chloride solution 10 mL/kg, twice a day, provided with adequate diet and clean tap water.
2.动物分组及给药方法2. Animal grouping and administration method
全部动物(清洁级雄性SD大鼠取90只,鼠龄8周,体重200±20g,随机分为正常组、模型对照组、阳性对照组、实施例1~3治疗组)从造模成功后第2日分别给予如下处理:正常组、模型对照组大鼠继续经口灌胃0.9%氯化钠溶液10mL/kg、2次/d;阳性对照组大鼠经口灌胃0.01g/mL维酶素混悬液10mL/kg,2次/d;实施例1~3治疗组给予速思麻而胃康颗粒混悬液10mL/kg,经口灌胃,2次/d。所有大鼠连续施加相关因素4周,配合充足饮食及饮水。All animals (90 clean-grade male SD rats, 8 weeks old, body weight 200±20g, randomly divided into normal group, model control group, positive control group, and Example 1-3 treatment groups) were obtained from the model after successful modeling. On the 2nd day, the following treatments were respectively given: the rats in the normal group and the model control group continued to be orally administered 10 mL/kg of 0.9% sodium chloride solution twice a day; the rats in the positive control group were administered orally 0.01 g/mL vitamin C Enzyme Suspension 10mL/kg, 2 times/d; Treatment groups in Examples 1-3 were given Susima Erweikang Granule Suspension 10mL/kg, orally, 2 times/d. All rats were continuously given relevant factors for 4 weeks, with adequate diet and drinking water.
3.观察方法与指标3. Observation methods and indicators
实验第16周末,大鼠禁食24h,禁水8h,10%水合氯醛溶液腹腔麻醉,心脏取血,分离血清,待测大鼠血清前列腺素E2(PGE2)及一氧化氮合酶(NOS)的水平。测定方法采用ELISA及硝酸还原酶法,严格按试剂盒说明书操作。距贲门和幽门1.5cm离断取出全胃,沿胃大弯侧剖开,冰生理盐水冲洗后,滤纸吸干铺开,取胃窦部1cm×0.5cm的胃组织,固定于10%的中性福尔马林溶液中用于做病理组织切片。At the end of the 16th week of the experiment, the rats were fasted for 24 hours and water for 8 hours, 10% chloral hydrate solution was intraperitoneally anesthetized, blood was taken from the heart, serum was separated, and the serum prostaglandin E 2 (PGE 2 ) and nitric oxide synthase of the rats were tested. (NOS) level. The assay method adopts ELISA and nitrate reductase method, and operates strictly according to the kit instructions. 1.5cm away from the cardia and pylorus, the whole stomach was cut off, and the whole stomach was cut open along the side of the greater curvature of the stomach. After flushing with ice saline, the filter paper was blotted and spread out. The gastric tissue of 1cm×0.5cm in the gastric antrum was taken and fixed in 10% medium. Sexual formalin solution for making pathological tissue sections.
(二)药理试验结果(2) Pharmacological test results
各治疗组与模型对照组相比,PGE2水平明显升高(P<0.01),NOS水平明显降低(P<0.01),说明各治疗组对慢性胃炎均有疗效;实施例1~3组与阳性对照组相比,差异显著(P<0.01),说明中药材微粉化颗粒的疗效优于阳性对照组。Compared with the model control group, the level of PGE 2 in each treatment group was significantly increased (P<0.01), and the level of NOS was significantly decreased (P<0.01), indicating that each treatment group had curative effect on chronic gastritis; Compared with the positive control group, the difference was significant (P<0.01), indicating that the curative effect of micronized granules of Chinese medicinal materials was better than that of the positive control group.
表6各组大鼠血清PGE2及NOS含量的比较Table 6 Comparison of serum PGE 2 and NOS content in each group of rats
注:与其他各组比较,★P<0.01;与阳性对照组比较,▲P<0.01。Note: Compared with other groups, ★ P <0.01; compared with positive control group, ▲ P < 0.01.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010179885.1A CN111249396A (en) | 2020-03-16 | 2020-03-16 | Traditional Chinese medicine for treating chronic gastritis and preparation method of micronized particles thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010179885.1A CN111249396A (en) | 2020-03-16 | 2020-03-16 | Traditional Chinese medicine for treating chronic gastritis and preparation method of micronized particles thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111249396A true CN111249396A (en) | 2020-06-09 |
Family
ID=70942020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010179885.1A Pending CN111249396A (en) | 2020-03-16 | 2020-03-16 | Traditional Chinese medicine for treating chronic gastritis and preparation method of micronized particles thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111249396A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110013540A (en) * | 2019-05-17 | 2019-07-16 | 宁夏医科大学 | A kind of traditional Chinese medicine composition for increasing gastrointestinal flora and preparation method and application thereof |
CN113413366A (en) * | 2021-06-30 | 2021-09-21 | 宁夏医科大学 | Dry-suspension oral in-situ gel for treating chronic gastritis and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102824503A (en) * | 2012-08-19 | 2012-12-19 | 甘肃省中医院 | Concentrated pill for treating atrophic gastritis and strengthening stomach and preparation method thereof |
CN107837338A (en) * | 2017-11-09 | 2018-03-27 | 宁夏医科大学 | A kind of Chinese medicine for treating atrophic gastritis and its precancerous lesion |
-
2020
- 2020-03-16 CN CN202010179885.1A patent/CN111249396A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102824503A (en) * | 2012-08-19 | 2012-12-19 | 甘肃省中医院 | Concentrated pill for treating atrophic gastritis and strengthening stomach and preparation method thereof |
CN107837338A (en) * | 2017-11-09 | 2018-03-27 | 宁夏医科大学 | A kind of Chinese medicine for treating atrophic gastritis and its precancerous lesion |
Non-Patent Citations (2)
Title |
---|
曹彬等: "复方蜥蜴散不同微粒组合剂治疗CAG阴虚络瘀证临床研究", 《辽宁中医杂志》 * |
郭利民等: "复方蜥蜴散不同微粒组合剂治疗大鼠慢性萎缩性胃炎的实验研究", 《辽宁中医杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110013540A (en) * | 2019-05-17 | 2019-07-16 | 宁夏医科大学 | A kind of traditional Chinese medicine composition for increasing gastrointestinal flora and preparation method and application thereof |
CN113413366A (en) * | 2021-06-30 | 2021-09-21 | 宁夏医科大学 | Dry-suspension oral in-situ gel for treating chronic gastritis and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103933128A (en) | Pharmaceutical composition for clearing away heat and toxic materials and preparation method thereof | |
CN111249396A (en) | Traditional Chinese medicine for treating chronic gastritis and preparation method of micronized particles thereof | |
CN113827687B (en) | A kind of traditional Chinese medicine preparation for treating thyroid nodules and preparation method thereof | |
CN102293951B (en) | Traditional Chinese medicine for treating toxic heat type influenza and preparation method thereof | |
CN104001131B (en) | A kind of Chinese medicine for oral administration preventing and treating stress ulcer | |
CN102552657B (en) | Chinese medicinal composition used for treating Newcastle disease of chicken | |
CN102940844B (en) | Medicine composition for treating dyspepsia | |
CN106138776A (en) | Chinese medicine composition for the treatment of headache and preparation method thereof | |
CN102228633A (en) | Traditional Chinese medicine for treating blood heat and toxic type nosebleed of children and preparation method thereof | |
CN115068540B (en) | A Chinese medicinal composition for treating nephropathy, decoction and preparation method thereof, and a pill and preparation method thereof | |
CN113082188B (en) | Preparation method of veterinary medicine against gastrointestinal inflammation | |
CN104436120B (en) | One kind treats chronic gastritis Chinese medicine composition | |
CN104857383B (en) | A kind of pharmaceutical composition for treating dental caries periapical inflammation and its application | |
CN104000883A (en) | Tablet for treating gastritis and preparing method and application thereof | |
CN104906491A (en) | Pure traditional Chinese medicine composition for treating infectious bursal disease of poultry and preparing methd thereof | |
CN114984179A (en) | Composition for treating or preventing mitiglinide adverse reaction and preparation method and application thereof | |
CN107375754A (en) | A kind of Chinese medicine for treating hyperthyroidism and preparation method thereof | |
CN105521113A (en) | External medicine for treating parotitis in children | |
CN103566275B (en) | Medicated wine containing Rhizoma Polypodiodis Nipponicae and preparation method thereof | |
CN110179857A (en) | Merge the formula of prevention and the treatment of hepatic lesion to acute critical pancreatitis | |
CN117752765A (en) | A traditional Chinese medicine composition for treating chronic gastritis and gastroduodenal ulcer and its preparation method and application | |
CN103933322A (en) | Throat-clearing tablets | |
CN109395027A (en) | A kind of Chinese patent drug week day 'Tongluowan ' for treating Bi condition disease | |
CN110721280A (en) | Traditional Chinese medicine composition for treating proventriculitis of poultry | |
CN106038727A (en) | Traditional Chinese medicinal composition for treating temporomandibular joint disorder syndrome and method for preparing preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200609 |